Raphael Pharmaceutical (RAPH) Return on Capital Employed (2021 - 2024)

Raphael Pharmaceutical has disclosed Return on Capital Employed across 4 years of filings, most recently posting 206.71% for Q4 2024.

• Return on Capital Employed for Q4 2024 came in at 206.71%, up 87973.0% year-over-year; the trailing twelve-month figure through Dec 2024 was 206.71% (up 87973.0% YoY), and the FY2025 annual result was 86.1%, down 15116.0% from the prior year.
• Return on Capital Employed came in at 206.71% for Q4 2024 at Raphael Pharmaceutical, up from 169.87% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 11375.51% in Q3 2022 to a low of 4121.21% in Q1 2023.
• The 4-year median for Return on Capital Employed is 495.19% (2024), against an average of 1478.73%.
• Peak annual rise in Return on Capital Employed reached 866562 bps in 2023, while the deepest fall reached 1021883 bps in 2023.
• Raphael Pharmaceutical's Return on Capital Employed stood at 3132.69% in 2021, then surged by 263 bps to 11375.51% in 2022, then plunged by 106 bps to 673.02% in 2023, then jumped by 131 bps to 206.71% in 2024.
• The last three Return on Capital Employed figures came in at 206.71% (Q4 2024), 169.87% (Q3 2024), and 783.66% (Q2 2024), per Business Quant data.